3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
HER2-positive Advanced Gastric Cancer
1
HER2 Overexpression
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Gene Expression Profiling
9
Surveys and Questionnaires
7
Blood Specimen Collection
7
Surgical Procedures, Operative
6
Polymerase Chain Reaction
6
Microarray Analysis
4
Immunohistochemistry
4
Base Sequence
4
Trabectedin
3
Therapeutics
3
Reverse Transcriptase Polymerase Chain Reaction
3
Radiation
3
Psychiatric Rehabilitation
3
Observation
3
Drug Therapy
3
Radiotherapy
2
Patient Reported Outcome Measures
2
Molecular Diagnostic Techniques
2
Methods
2
In Situ Hybridization, Fluorescence
2
Gene Rearrangement
2
DNA Methylation
2
Amplified Fragment Length Polymorphism Analysis
2
trastuzumab deruxtecan
1
pazopanib
1
liposomal doxorubicin
1
fluorodopa F 18
1
eribulin
1
Watchful Waiting
1
Urine Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Sarcoma
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-05-01
DP-04
AstraZeneca
Recruiting
100 enrolled